To achieve the beneficial activation of cytotoxic T lymphocytes to enhance cancer immunotherapy, a variety of engineering strategies have concentrated on altering the binding affinity of IL-2 to distinct receptor subunits (Table 1; Figures 2B, C). Here, IL2 is linked to cancer.